Photodynamic Therapy (PDT) — Cost, Top Hospitals & Success Rates | MyMedicPlus

Photodynamic therapy (PDT) is a minimally invasive, two-stage medical treatment that exploits the interaction of three essential components: a photosensitising drug, a specific wavelength of light, and molecular oxygen. When the photosensitiser accumulates in target tissue and is activated by light, it undergoes a photochemical reaction that generates highly reactive oxygen species — principally singlet oxygen (¹O₂) — which cause irreversible oxidative damage to cell membranes, mitochondria, and nuclear DNA. The resulting cascade triggers both apoptosis (programmed cell death) and necrosis, selectively destroying the lesion while largely sparing surrounding healthy tissue.

The photochemical reaction occurs via two pathways. The Type II reaction — the dominant mechanism in most clinical PDT — transfers energy from the excited photosensitiser triplet state directly to molecular oxygen, producing singlet oxygen. The Type I reaction involves electron transfer to substrates, generating free radicals including superoxide and hydroxyl radicals. Both pathways converge to produce cytotoxic oxidative stress within the target lesion.

PDT has regulatory approval and NICE guidance across a growing spectrum of oncological, dermatological, and ophthalmological indications. In dermatology, aminolaevulinic acid (ALA) and its methyl ester methyl aminolaevulinate (MAL) are the most widely used photosensitisers, accumulated as protoporphyrin IX (PpIX) in proliferating epidermal cells and activated by red light at approximately 630 nm. In ophthalmology, verteporfin (Visudyne) activated by 689 nm laser is the established approach for choroidal neovascularisation in wet AMD. In oncology, Foscan (temoporfin) treats palliative and early head and neck squamous cell carcinoma, while TOOKAD/WST11 is used in vascular-targeted PDT for low-risk localised prostate cancer.

A critical clinical advantage of PDT is its repeatability: unlike radiotherapy, the same tissue can be retreated without cumulative dose-limiting toxicity to normal organs, making it ideal for managing field cancerisation and recurrent lesions on chronically sun-damaged skin.

PDT addresses a broad and expanding range of conditions across multiple medical specialties. The choice of photosensitiser and light delivery system is tailored to the specific indication and tumour depth.

Dermatological Conditions (NICE TA155 / TA163)

• Actinic keratoses (AK): Grade I–III lesions, especially in field cancerisation where multiple lesions cover large areas of scalp, face, or dorsum of hands. PDT treats the entire at-risk field simultaneously.
• Bowen's disease (SCC in situ): Large lesions (>2 cm) on trunk and limbs; lesions in cosmetically sensitive areas or sites with poor healing (lower legs). Curettage preparation improves penetration.
• Superficial basal cell carcinoma (sBCC): Lesions ≤3 cm in diameter and ≤2 mm depth, particularly on the face or areas where surgery would leave significant scarring. NICE TA155 recommends PDT as an alternative to surgery for sBCC.
• Nodular BCC: Thin nodular lesions; lower cure rates than surgery but acceptable in selected patients.

Ophthalmological

• Wet (neovascular) age-related macular degeneration (AMD): Verteporfin PDT targets choroidal neovascularisation (CNV), particularly predominantly classic CNV. It is increasingly combined with anti-VEGF therapy for synergistic benefit.
• Polypoidal choroidal vasculopathy (PCV): PDT plus anti-VEGF (ranibizumab) is the evidence-based treatment per the EVEREST II trial.

Urological

• Low-risk localised prostate cancer: TOOKAD (WST11) vascular-targeted PDT is licensed following the Phase III PCM301 trial (Azzouzi et al., 2017), offering focal therapy for Gleason 6 disease with minimal impact on urinary and sexual function.

Head, Neck, and Thoracic Oncology

• Advanced head and neck squamous cell carcinoma: Foscan (temoporfin) provides palliative and curative-intent PDT for accessible lesions.
• Endobronchial early-stage lung cancer: Porfimer sodium (Photofrin) PDT via bronchoscope for central early-stage non-small cell lung cancer.
• Oesophageal cancer: Palliation and treatment of superficial lesions; largely superseded by radiofrequency ablation for Barrett's dysplasia.

Patient selection for PDT depends on lesion characteristics, photosensitiser suitability, and the patient's ability to adhere to post-treatment light avoidance protocols. A thorough clinical assessment — often including dermoscopy, reflectance confocal microscopy, or high-frequency ultrasound — is performed to confirm lesion depth and tumour subtype before treatment.

Ideal Candidates for Skin PDT

• Patients with multiple AK lesions covering large surface areas (field cancerisation) where destructive methods would cause significant morbidity or poor cosmetic outcomes
• Superficial BCC or Bowen's disease on cosmetically sensitive areas (face, scalp) or on the lower legs where wound healing is poor
• Patients who are unsuitable for surgery due to anticoagulation, systemic illness, or age
• Patients seeking a scar-free alternative for facial lesions
• Immunosuppressed patients (e.g. transplant recipients) with multiple synchronous lesions

Contraindications

• Porphyria: Absolute contraindication for all ALA/MAL-PDT formulations
• Known hypersensitivity to the photosensitiser or any excipient
• Deep lesions: Tumours invading deep dermis, subcutaneous tissue, cartilage, or bone are not suitable for cutaneous PDT
• Unable to comply with photosensitivity precautions: Patients who cannot avoid light exposure post-treatment are not suitable candidates for systemic photosensitisers (Foscan)
• Pregnancy and breastfeeding: Limited safety data; caution required
• Concurrent photosensitising medications: Tetracyclines, thiazides, and certain NSAIDs may increase photosensitivity risk

The dermatologist or specialist oncologist will document tumour histology (ideally from a previous punch biopsy), measure tumour diameter, and confirm absence of ulceration or morphoeic BCC features before offering PDT as the primary treatment modality.

PDT protocols differ substantially depending on the indication, the photosensitiser used, and the delivery system. The following outlines the main clinically validated options.

1. Conventional (Lamp-Based) MAL-PDT / ALA-PDT — Dermatology

• Lesion preparation: Curettage or debulking of surface scale, removal of surface keratin with acetone or gentle abrasion to improve penetration
• Photosensitiser application: MAL cream (Metvixia, 160 mg/g) or ALA cream/patch applied 1–2 mm beyond lesion margin under occlusive dressing
• Incubation: 3 hours in a dark environment allowing conversion to PpIX
• Light activation: Red light at 630 nm, dose 37 J/cm² (MAL) or 75–100 J/cm² (ALA)
• Repeat: Second session one week later per NICE TA155 protocol

2. Daylight PDT (dPDT)

• MAL or ALA is applied, sunscreen applied immediately, and the patient sits in natural outdoor daylight or a daylight-simulating cabin for 2 hours
• Daylight gradually activates PpIX at low intensity, providing significantly less pain than conventional lamp-based PDT with comparable efficacy for mild-to-moderate AK
• Endorsed by the European Dermatology Forum; suitable when ambient temperature ≥10°C and cloud cover <80%

3. Verteporfin (Visudyne) PDT — Ophthalmology

• Intravenous infusion of verteporfin 6 mg/m² over 10 minutes
• Diode laser (689 nm, 50 J/cm²) applied to the CNV lesion 15 minutes after infusion commencement
• Retreatment every 3 months based on OCT and fluorescein angiography response
• Currently often combined with intravitreal anti-VEGF therapy

4. Foscan (Temoporfin) — Head and Neck Cancer

• IV injection (0.15 mg/kg), followed by a 96-hour incubation period allowing tissue accumulation
• 652 nm laser activation delivering 20 J/cm²
• Strict light avoidance for minimum 15 days post-injection
• Provides precise control of depth of necrosis based on irradiation parameters

5. TOOKAD/WST11 — Vascular-Targeted Prostate PDT

• IV infusion immediately followed by transperineal optical fibre laser activation (753 nm)
• Performed as a day-case procedure under general or spinal anaesthesia
• Targets tumour vascular endothelium, causing ischaemic necrosis of the prostate lesion
• MRI-guided fibre placement enables focal or hemi-ablation

PDT offers a compelling combination of clinical efficacy and patient-centred advantages that make it uniquely valuable in specific clinical scenarios.

• Tissue-sparing selectivity: Photosensitisers accumulate preferentially in rapidly proliferating or metabolically active cells, sparing the surrounding dermis, nerves, and blood vessels. This results in excellent cosmetic outcomes — particularly important for facial and lower-leg lesions.
• Field treatment capability: Unlike surgery or cryotherapy, PDT can simultaneously treat an entire area of field cancerisation rather than individual lesions, reducing the risk of new AK and SCC development in the treated field.
• Repeatability without cumulative toxicity: PDT can be repeated multiple times at the same site without the cumulative damage associated with radiotherapy, making it the preferred modality for managing recurrent lesions in immunocompromised patients.
• High clearance rates for approved indications: Clinical trials demonstrate 85–92% complete response rates for AK and Bowen's disease at 3 months, 85–87% for sBCC at 12 months. Cosmetic outcomes are rated "good" to "excellent" in over 90% of cases.
• Outpatient / office-based procedure: No general anaesthesia required for skin PDT; patients leave immediately after treatment.
• Organ function preservation in oncology: TOOKAD PDT for prostate cancer demonstrates significantly lower rates of urinary and erectile dysfunction than radical prostatectomy or radiotherapy in the PCM301 trial, making it attractive for quality-of-life-conscious patients with low-risk disease.
• Immune modulation: PDT has been shown to stimulate anti-tumour immune responses via damage-associated molecular patterns (DAMPs) and dendritic cell activation, potentially contributing to long-term tumour control.
• Low systemic toxicity: Topical ALA/MAL formulations have negligible systemic absorption, minimising the risk of drug side effects.

PDT is generally well tolerated but carries specific side effects related to the photosensitiser and the phototoxic reaction. Patients should be counselled comprehensively before treatment.

Local Phototoxic Reactions (expected and manageable)

• Pain during light activation: A burning, stinging, or prickling sensation rated 4–7 out of 10 by most patients. Managed with cooling air fans, cold water spray, topical anaesthetic (lidocaine cream), or regional nerve block for large-area treatment. Daylight PDT substantially reduces this.
• Erythema and oedema: Occurs in virtually all patients within hours of treatment; peaks at 24–48 hours; part of the expected phototoxic response.
• Vesiculation and exudation: Small blisters may develop, particularly on thin-skinned or lower-leg sites. Usually resolves within 1–2 weeks.
• Crusting and healing phase: Treated area forms a crust that separates over 2–4 weeks; patients should avoid picking crusts to prevent scarring.

Medium-Term Side Effects

• Hypo- or hyperpigmentation: Transient pigment changes in the treated area; usually resolves within 3–6 months. Regular sunscreen use accelerates recovery.
• Post-treatment photosensitivity: After ALA/MAL, treated skin is photosensitive for 24–48 hours. After systemic Foscan, whole-body photosensitivity persists for up to 15 days — patients must avoid bright indoor and outdoor light and cover all exposed skin.

Treatment Outcome Limitations

• Lower cure rates for thick lesions: Nodular BCC has approximately 70–75% 5-year clearance with PDT versus >95% with surgical excision. Thick lesions require adequate curettage debulking before treatment.
• Recurrence risk: AK and Bowen's disease may recur in the treated field, requiring surveillance and possible retreatment.

Rare Serious Complications

• Allergic contact dermatitis to MAL cream components
• Acute severe visual decrease (<1% with verteporfin PDT)
• Back pain during verteporfin infusion (resolves after slowing infusion rate)
• Photosensitiser-related nausea or headache with systemic agents

Structured post-treatment follow-up is essential to assess therapeutic response, manage healing complications, and detect early recurrence.

Skin PDT Follow-Up

• 3 months: First clinical review — evaluate complete versus partial response. Dermoscopy assesses residual lesion activity. Persistent lesions may warrant re-treatment with PDT or alternative modality.
• 6 months: Secondary assessment, particularly for sBCC. Incomplete responders should be discussed in a multidisciplinary team (MDT) meeting to consider surgical excision.
• 12 months and annually: Long-term dermatological surveillance for patients with extensive actinic damage, multiple NMSC, or immunosuppression. Total-body skin examination is recommended.
• Wound care guidance: Patients receive written instructions to keep the treated area clean and moist; petroleum jelly or a non-adherent dressing is used for the first 1–2 weeks. Sun avoidance and daily SPF 50+ application to treated and adjacent areas is mandatory.

Ophthalmic PDT Follow-Up

• OCT and fluorescein angiography at 3-month intervals to evaluate CNV activity
• Retreatment is guided by evidence of persistent or recurrent CNV leakage and subretinal fluid on OCT
• Visual acuity, contrast sensitivity, and Amsler grid monitoring at each visit

Prostate (TOOKAD) PDT Follow-Up

• 6 months: Multiparametric MRI (mpMRI) and PSA measurement; template-mapping biopsy to confirm oncological control
• 2 years: Repeat mpMRI and PSA; urinary and erectile function questionnaires (IPSS, IIEF)
• Annual PSA surveillance thereafter; patients with residual or progressive disease are referred for radical treatment discussion

Head and Neck Cancer PDT (Foscan) Follow-Up

• Clinical examination and endoscopy at 3 and 6 months
• CT or PET-CT imaging to assess treatment response in advanced cases
• MDT review for patients with evidence of recurrence or progression

The cost of PDT varies considerably by indication, photosensitiser used, geographic location, and healthcare system. Understanding the cost landscape helps patients make informed decisions about where and how to access treatment.

United Kingdom

• NHS: ALA/MAL-PDT is available on the NHS for AK, Bowen's disease, and sBBC in line with NICE TA155 and TA163 — no direct patient cost for eligible patients
• Private skin PDT: £300–£800 per session; two sessions typically required. Total course cost: £600–£1,600
• Verteporfin ophthalmic PDT: £600–£1,200 per session (now largely superseded by anti-VEGF which is NHS-funded)
• Head/neck cancer PDT (Foscan): £2,000–£5,000 per treatment course; available in selected cancer centres
• Prostate TOOKAD PDT: £8,000–£15,000 for a single treatment session; currently available mainly in private urology centres or clinical trial settings

India

• Skin PDT: ₹5,000–₹20,000 per session in metropolitan cities; lower in tier-2 centres
• Prostate PDT: Limited availability; few specialised urology centres offer this procedure

South-East Asia (Thailand, Malaysia, Singapore)

• Skin PDT: USD 300–800 per session in leading dermatology clinics

Key Cost Determinants

• Number and size of lesions treated per session
• Photosensitiser acquisition cost (MAL cream is more expensive than compounded ALA)
• Type of light delivery system (lamp vs. laser)
• Specialist dermatologist, ophthalmologist, or oncologist fees
• Number of sessions required and need for retreatment
• Whether treatment is NHS-funded or privately arranged
• Hospital or outpatient clinic overheads

Several evidence-based alternatives exist for conditions treated with PDT. The choice between PDT and alternative therapies depends on lesion type, depth, patient preference, and available expertise.

For Actinic Keratoses

• Cryotherapy (liquid nitrogen): First-line for isolated, well-defined AK lesions; fast, cheap, and office-based but impractical for field cancerisation and produces scarring on thin-skinned sites
• Topical 5-fluorouracil (Efudix 5%): Effective field treatment over 3–6 weeks; causes significant inflammation and sun sensitivity but is low-cost and patient-administered at home
• Imiquimod 5% cream (Aldara): Immune-modulating agent applied 3 times weekly for 4–16 weeks; activates innate immunity to clear AK and early BCC without a procedure
• Diclofenac 3% gel (Solaraze): Milder option for mild AK; applied twice daily for 60–90 days; minimal inflammation but lower clearance rates
• Tirbanibulin 1% ointment (Klisyri): Newer NICE-approved topical for AK; 5-day once-daily application; dual mechanism inhibiting Src kinase and tubulin polymerisation
• Laser ablation (CO₂ or Er:YAG): Effective for scalp AK field cancerisation; excellent results with full-face resurfacing

For Basal Cell Carcinoma

• Surgical excision: Gold standard for all BCC subtypes; provides histological margin control; cure rates >95% for primary BCC
• Mohs micrographic surgery: Highest cure rates (>99%) for high-risk BCC on face, ears, and nose; tissue-sparing
• Curettage and electrodessication: Office-based option for small superficial BCC in non-critical sites
• Radiotherapy: For patients unsuitable for surgery; especially useful for BCC in elderly patients or around the eye
• Hedgehog pathway inhibitors (vismodegib, sonidegib): Systemic therapy for locally advanced or metastatic BCC

For Wet AMD

• Anti-VEGF intravitreal injections (ranibizumab, bevacizumab, aflibercept, brolucizumab): Now the first-line standard of care, superseding verteporfin PDT monotherapy for most AMD subtypes

For Prostate Cancer

• Active surveillance: Monitoring without immediate treatment for very low-risk Gleason 6 disease
• Radical prostatectomy or radiotherapy: Definitive treatment for intermediate-to-high-risk localised prostate cancer
• High-intensity focused ultrasound (HIFU): Focal ablation alternative to TOOKAD PDT